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Abstract 
Primary human hepatocytes are commonly used to evaluate liver drug metabolism and toxicity. Pluripotent 
stem cell derived hepatocytes (SCDHs) have the potential to overcome access and function-related limitations 
associated with primary hepatocytes. SCDHs may also provide an improved system for evaluating genotype-
phenotype relationships, e.g. cytochrome P450 (CYP) gene polymorphisms and their impact on drug metabolism 
and toxicity. However, in order for SCDHs to become routinely used in preclinical drug metabolism and toxicity 
screening, they must demonstrate reproducible activity of drug metabolism proteins, particularly the oxidative 
CYP enzymes. We characterized the differentiation status of SCDHs, with emphasis on the expression and 
functional capacity of drug-metabolizing enzymes, and genetically profiled the commonly used WiCell® hESC 
lines, focusing on CYP2D6 in our analysis. An assay of enzymatic function in SCDHs using a CYP cocktail assay 
designed to measure 8 different isozymes revealed only minimal activity for CYP3A, below that observed in 
primary hepatocytes. With regard to CYP2D6 gene copy number variation, we found the H1 line has only one 
gene copy, which also harbors the CYP2D6*41 splicing defect, predictive of a CYP2D6 poor/intermediate 
metabolizer. We identified no CYP2D6 gene duplications, indicating no representative ultra-rapid metabolizer. 
The H7 and H14 lines are heterozygous for the non-functional CYP2D6*4 variant resulting in a predicted 
intermediate metabolizer phenotype. In addition, we compared the penetrance of the CYP2D6*41 splicing 
defect in SCDHs and liver tissue via reverse-transcription PCR assay. We found incomplete penetrance of the 
CYP2D6*41 allele in liver tissue and variable penetrance in SCDHs. Based on gene expression profiling, SCDHs 
most closely resemble fetal hepatocytes, especially with regards to AFP, CYP3A7 and FMO1 expression. Finally, 
these studies indicate a low degree of genetic diversity of pharmacogenetically-relevant genes in the WiCell® 
hESC lines. 
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Introduction 
Preclinical screening and characterization of the metabolic pathways of a new drug is a necessary part of 
its development and can be used to aid in predicting drug bioavailability, drug efficacy, drug-drug 
interactions, and drug toxicity. The main family of enzymes responsible for oxidative drug metabolism is the 
Cytochrome P450s (CYPs), in particular members of just three subfamilies (CYP1, CYP2 and CYP3) are 
primarily responsible for the metabolism of most drugs [1]. The drug-metabolizing CYPs are highly 
expressed in the liver, making it the primary organ to study for the metabolism, detoxification and 
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elimination of drugs, and the focus of drug optimization and safety studies [2, 3]. Pharmacogenetic 
variability, in drug-metabolizing enzymes such as the CYPs, can influence an individual’s susceptibility to 
drug toxicity, contributing to observed adverse drug reactions (ADRs) [4]. Drug-drug interactions are a 
major concern of pharmaceutical companies, particularly with respect to ADRs, a leading cause of 
preventable death in the United States [4]. Primary human hepatocytes are the most physiologically 
relevant in vitro preclinical screening system used to evaluate drug metabolism in the liver [5]. This is due 
to their high-expression of phase I and II drug-metabolizing enzymes, as well as phase III transporters. 
However, primary human hepatocytes have certain features that limit their utility in preclinical drug 
development, including: high donor variability, uncertain availability, short-term survival in culture, and a 
rapid loss of hepatic functions in culture [5-7]. Stem cell derived hepatocytes (SCDHs) may provide an 
alternative or complementary in vitro tool to primary human hepatocytes for evaluating drug metabolism 
and liver toxicity characteristics. Pluripotent stem cells have high self-renewal abilities, providing a 
potentially unlimited source of hepatocytes of defined genotype and phenotype [6, 8]. In order for SCDHs 
to become routinely used in preclinical drug metabolism and toxicity screening, they must demonstrate 
reproducible activity of drug metabolism proteins, particularly the oxidative CYP enzymes. Additionally, it 
would be ideal if SCDHs produced metabolic activities comparable to that of primary human hepatocytes. 
Since SCDHs have defined genotypes, they may also provide an improved system for evaluating genotype-
phenotype relationships, e.g. CYP gene polymorphisms and their impact on drug metabolism and toxicity, 
and in particular drug-induced liver injury. 
Overall, published studies demonstrate that SCDHs generated from either human embryonic stem cells 
(hESCs) or induced pluripotent stem cells (iPSCs), do express CYPs and other drug-metabolizing enzymes, 
however they seem to be at levels below those in primary human hepatocytes. In addition, the majority of 
studies have also reported SCDHs as still expressing α-fetoprotein (AFP), which is highly expressed in fetal 
livers and not typically expressed in healthy adult livers, indicating the cells may still be in an immature 
state. Despite the advances made in generating SCDHs, the biggest limitation in the field to date is the 
inability to reproducibly and consistently generate mature hepatocytes with high levels of functional drug 
metabolizing enzymes. In order for SCDHs to be successfully used as an in vitro assay platform for 
metabolite profiling, this is something that must be overcome. This indicates there is a significant need for 
improvement on generating and characterizing SCDHs, particularly with regards to their metabolic capacity 
as it compares to primary human hepatocytes. We sought to further investigate the state of SCDHs as they 
compare to cryopreserved human hepatocytes, with emphasis on the expression and functional capacity of 
drug-metabolizing enzymes. This was done in part through gene expression profiling of pluripotency 
markers, hepatocyte markers, drug-metabolizing enzymes and transporters. To evaluate the functional 
capacity of CYP enzymes in SCDHs, metabolite formation was assessed using a CYP cocktail approach and 
LC-MS/MS. Additionally, to demonstrate the utility of SCDHs in pharmacogenetic predictive screening, we 
sought to genetically profile the commonly used WiCell® hESC lines H1, H7, H9, H13 and H14 using the 
Affymetrix DMET™ Plus chip array. This array covers approximately 2000 polymorphisms in Absorption, 
Distribution, Metabolism and Excretion (ADME) relevant genes. We focused on CYP2D6 in our analysis in 
utilizing SCDHs for genotype-phenotype predictions, given its highly polymorphic nature and role in 
metabolizing about 20 % of marketed drugs [9, 10]. In terms of testing genotype-phenotype relationships 
for CYP2D6 in SCDHs, we assessed the penetrance of CYP2D6*41, a splicing defect which results in a 
CYP2D6 splice product lacking exon 6, through use of a reverse-transcription PCR assay.  
 
Voellinger and Kelly  ADMET & DMPK 4(2) (2016) 62-83 
64  
Experimental 
Pluripotent Stem Cells 
The hESC lines H1 (WA01), H7 (WA07), H9 (WA09), H13 (WA13), and H14 (WA14) were obtained from 
WiCell® Research Institute (Madison, WI, http://www.wicell.org) and propagated at the University of 
Washington (UW) Institute for Stem Cell and Regenerative Medicine. All studies were conducted under 
approval of the University of Washington Embryonic Stem Cell Research Oversight Committee.  
Cryopreserved Human Hepatocytes and HepaRG Cells 
Cryopreserved human hepatocyte lots HU8110 and HU8114 were purchased from Invitrogen (Carlsbad, 
CA) and cultured according to manufacturer’s instructions. Briefly, cells were thawed in CHRM® media and 
plated in Williams Medium E supplemented with Hepatocyte Plating Supplement Pack from Invitrogen on 
24-well plates coated with rat Collagen I. Following a 6-hour incubation period to allow for cell attachment, 
the media was changed to Williams Medium E supplemented with Hepatocyte Maintenance Supplement 
Pack from Invitrogen. Cells were maintained in this hepatocyte maintenance media for 4 days with daily 
fluid changes.  
Cryopreserved human hepatocyte lots HUM4012 and HUM4034 were purchased from Triangle Research 
Labs (TRL, Research Triangle Park, NC) and cultured according to manufacturer’s instructions. Briefly, cells 
were thawed in Animal Thawing and Plating Medium from TRL and plated in Human Hepatocyte Plating 
Medium from TRL supplemented with the plating supplement on 24-well plates coated with rat Collagen I. 
Following a 6-hour incubation period to allow for cell attachment, the media was changed to Hepatocyte 
Maintenance Medium supplemented with the maintenance supplement from TRL. Cells were maintained in 
this hepatocyte maintenance media for 3 days with daily fluid changes. In addition, plated primary human 
hepatocytes were kindly gifted from Dr. David Eaton’s lab at the University of Washington.  
Undifferentiated HepaRG cells were obtained from Biopredic International (Saint-Gregoire, France). 
Undifferentiated HepaRG cells were cultured in Williams Medium E (Invitrogen) supplemented with growth 
supplement (Biopredic) for 2 weeks with fluid changes every 2-3 days. After 2 weeks in culture, HepaRG 
cells were differentiated using a 50:50 mix of media supplemented with growth supplement and Williams 
Medium E supplemented with differentiation supplement (Biopredic). After 2 days in culture, cells were 
switched to 100 % media with differentiation supplement. Cells were maintained in media with 
differentiation supplement for 2 weeks, with fluid changes every 2-3 days. 
Hepatocyte Differentiation 
hESCs were cultured on mouse embryonic fibroblasts (MEFs) before being transferred to Matrigel™ (BD 
Biosciences, San Diego, CA)-coated plates using mTeSR™1 media (Stem Cell Technologies, Vancouver, 
Canada). Hepatocyte differentiation was induced in three stages, as published by Hay et al [11, 12]. Briefly, 
differentiation was initiated at 60-70 % confluence by replacing the mTeSR™1 media with priming medium: 
RPMI 1640 containing 1xB27 (Invitrogen), 100 ng/mL Activin A (PeproTech, Rocky Hill, NJ), and 50 ng/mL 
Wnt3a (R&D Systems, Minneapolis, MN). After 72 hours, with daily media changes, the cells were switched 
to differentiation medium: Knockout-DMEM containing 20 % Knockout Serum Replacement, 1 mM 
glutamine, 1 % nonessential amino acids, 0.1 mM β-mercaptoethanol (Invitrogen), and 1 % dimethyl 
sulfoxide (DMSO) (Sigma, St Louis, MO) for a further 5 days. Lastly, the cells were switched to maturation 
media: Hepatozyme containing 10 μM hydrocortisone 21-hemisuccinate, 2 mM glutamine, 10 ng/mL 
hepatocyte growth factor and 20 ng/mL oncostatin M (R&D Systems). The media was changed every other 
day during maturation until the end of differentiation around day 17. To investigate the inductive capacity 
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of CYP enzymes, cells were cultured in the presence of 10 μM rifampicin (Sigma), 1 mM phenobarbital 
(Sigma), or 0.1 % DMSO as a vehicle control for 72 hours before the end of differentiation on Day 17. 
Additional H9 SCDHs were a kind gift from Dr. David Hay at the University of Edinburgh. 
SCDHs used for the CYP cocktail assay were differentiated using a slightly different method. Briefly, 
hESCs were cultured on Matrigel™ plates using mTeSR™1 media as above. Prior to the start of 
differentiation, cells were passaged with 0.05 % Trypsin-EDTA (Invitrogen) to single cells and 1 x 105 cells 
per well were plated on fresh Matrigel™ coated 24-well plates in mTeSR™1 media containing 10 μM Y-
27632 (ROCK inhibitor) (Selleck Chemicals, Houston, TX). Cells were cultured in these conditions for 24 
hours and then differentiation was initiated with priming medium as described above.  
Fetal and adult liver tissue 
Six human fetal liver tissue samples were obtained from the Birth Defects Research Laboratory at the 
University of Washington, courtesy of Dr. Qingcheng Mao. Fetal liver tissues were obtained with Use of 
Non-Identifiable Biological Specimens/Data and so exempt from Human Subjects review. Human liver tissue 
samples were obtained from the UW School of Pharmacy Human Liver Bank (Seattle, WA) [13].  
Immunocytochemistry 
Cells on day 17 of differentiation were fixed with ice-cold methanol for 10-15 minutes, washed with PBS, 
and permeabilized with 0.5 % Triton X-100 for 2 minutes. Following a PBS wash, cells were blocked with 2 % 
normal goat serum for 1 hour at room temperature. Cells were then washed with PBS again and incubated 
overnight at 4 °C with the following primary antibodies: anti-AFP at 1:600 (Dako, Carpinteria, CA); anti-
albumin at 1:1000 (a gift from Dr. Jean Campbell, Department of Pathology, University of Washington); 
anti-HNF4α at 1:100 (Santa Cruz Biotechnology, Dallas, TX); and anti-CYP3A at 1:100 (Santa Cruz 
Biotechnology). After washing with PBS, cells were incubated with Alexa Fluor® 488 secondary antibodies at 
1:1000 for 1 hour at room temperature (Invitrogen). Finally, cells were mounted with SlowFade® Gold 
Antifade Mount with DAPI (Invitrogen). 
DNA Isolation and Genotyping 
Genomic DNA was isolated from the WiCell® hESC lines using the Qiagen (Valencia, California) DNeasy 
blood and tissue kit according to the manufacturer’s recommendations. DNA was quantified on a BioRad 
SmartSpec Plus (Hercules, CA) spectrophotometer, measuring absorbance and 260/280 nm ratio. 
Genotyping of hESC lines H1, H7, H9, H13, and H14 was conducted using the Affymetrix DMET™ Plus Array 
according to manufacturer’s recommendations (Santa Clara, CA, http://www.affymetrix.com). Analysis was 
performed using Affymetrix’s DMET™ Console Analysis Software. 
Quantitative real-time PCR (qRT-PCR) and CYP2D6 Copy Number Assay 
RNA was isolated using TRIzol Reagent from Invitrogen (Carlsbad, CA) following manufacturer’s 
recommendations, and quantified on a BioRad SmartSpec Plus (Hercules, CA) spectrophotometer, 
measuring absorbance and 260/280 nm ratio. Complementary DNA (cDNA) was synthesized using 1 μg total 
RNA and the Taqman® Reverse Transcription Reagents in 10 μL total volume (Invitrogen). Following 
synthesis, cDNA was diluted to 5 ng/μL and 20 ng was used for qRT-PCR analysis. qRT-PCR for CYPs 3A4, 
3A7, 1A2, 1B1, 2A6, 2B6, 2C9, 2C19, 2C8, 2D6, 2E1, FMO1, FMO3, UGT1A1, UGT1A6, UGT2B4, UGT2B7, 
GSTT1, GSTM1, GSTP1, OATP1B1, OATP1B3, MRP2, ABCB1, ABCG2, ATP7B, NANOG, SOX2, OCT4, ALB, AFP, 
HNF4α, CAR, PXR, AHR, and POR was carried out using Taqman® Gene Expression Assays from Applied 
Biosystems (Foster City, California) with GUSB as the housekeeping gene. CYP2D6 copy number was 
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assessed using a TaqMan® Copy Number assay from Applied Biosystems (Hs00010001_cn) with RNAseP as 
a single copy gene calibrator, according to the manufacturer’s recommendations, using their SDS 2.3 and 
Copy Caller v1.0 programs. One copy and more than two copy positive controls were identified in the UW 
School of Pharmacy Human Liver Bank (Seattle, WA) through sequencing analysis as previously described. 
CYP2D6*41 reverse-transcription PCR Assay 
Total RNA was isolated using TRIzol Reagent (Invitrogen), following manufacturer’s recommendations, 
and quantified on a BioRad SmartSpec Plus (Hercules, CA) spectrophotometer, measuring absorbance and 
260/280 nm ratio. cDNA was synthesized using the TaqMan Reverse Transcription kit (Invitrogen) from 1 μg 
of total RNA. To detect the presence of exon 6 in CYP2D6, a 579-bp PCR fragment spanning a region from 
exon 5 to exon 8 was amplified with primers Exon5/8For3 (5’-TCCCCGTCCTCCTGCATA-3’) and Exon5/8Rev3 
(5’-GTGTTCGGGGTGGAAGCG-3’) (IDT, Coralville, Iowa). If exon 6 is skipped due to the presence of 
CYP2D6*41, a smaller PCR fragment of 438-bp is expected. PCR was run under the following conditions, 95 
°C for 5 minutes, 92 °C for 20 seconds, 59.6 °C for 30 seconds, 72 °C for 2 minutes, 72 °C for 10 minutes, 4 
°C hold, repeating steps 2-4 for 40 cycles. PCR products were run on 1.5 % agarose gels and visualized by 
staining with 0.5 μg/mL ethidium bromide (BioRad). Human liver samples used for this study were obtained 
from the UW School of Pharmacy Human Liver Bank. Genotyping for CYP2D6*41 was done using an existing 
TaqMan® assay (C_34816116) (Applied Biosystems). 
CYP cocktail assay and LC-MS/MS 
Two CYP cocktail assays developed in Dr. Jashvant Unadkat’s lab at the University of Washington were 
used to assess functional CYP activity [14]. Cocktail A assesses CYPs 3A, 2C9, 1A, 2D6, 2A6, and cocktail B 
assesses CYPs 2B6, 2C8, and 2E1. Acetaminophen, amodiaquine dihydrochloride dihydrate, bupropion, 
chlorzoxazone, coumarin, phenacetin, and tolbutamide were purchased from Sigma. Dextromethorphan, 
d5-diazepam, dextrorphan, testosterone, n-desethylamodiaquine, hydroxy-bupropion, 4-
hydroxytolbutamide, 6-hydroxychlorzoxazone, and 6-β-hydroxytestosterone were purchased from Cerilliant 
(Round Rock, TX). 7-hydroxycoumarin was a kind gift from Dr. Unadkat’s lab.  
For the analytical assays, a set of metabolite standards with nine calibration points and a separate set of 
three quality control (QC) samples were prepared. The calibrator concentration ranges were: 
acetaminophen, 0.031-8 μM; OH-bupropion, 0.002-0.5 μM; 4-OH-tolbutamide, 0.013-3.3 μM; 6-OH-
testosterone, 0.31-80 μM; 6-OH-chlorzoxazone, 0.0625-16 μM; 7-OH-coumarin, 0.0042-1.08 μM; n-
desethylamodiaquine, 0.0083-2.12 μM; dextrorphan, 0.0017-0.44 μM. The QC concentration ranges were: 
acetaminophen, 0.125-4 μM; OH-bupropion, 0.0078-0.25 μM; 4-OH-tolbutamide, 0.052-1.66 μM; 6-OH-
testosterone, 1.25-40 μM; 6-OH-chlorzoxazone, 0.25-8 μM; 7-OH-coumarin, 0.017-0.54 μM; n-
desethylamodiaquine, 0.033-1.06 μM; dextrorphan, 0.0068-0.22 μM. All calibrator and QC points were 
made in hepatozyme maturation media, an equal volume of calibrator or QC was then added to an equal 
volume of acetonitrile containing 0.06 ng/μL of internal standard d5-diazepam and centrifuged at 13,000 
rpm for 10 minutes. The supernatant was removed and stored at 4 °C until analysis. 
CYP assay incubations were performed on Day 17 SCDHs and cryopreserved hepatocytes lots HUM4012 
and HUM4034. Incubations were performed as described by Liu et al., with some modifications [14]. Briefly, 
standard stock mixtures of cocktail A and B were prepared and diluted in hepatozyme maturation media for 
cell incubations to the following final concentrations: Cocktail A, tolbutamide, 75 μM, testosterone, 100 
μM, dextromethorphan, 5 μM, coumarin, 0.5 μM, phenacetin, 50 μM; Cocktail B, bupropion, 100 μM, 
amodiaquine, 4 μM, chlorzoxazone, 25 μM. The final concentration of organic solvent in cell incubations 
was 1 %. Cocktail incubations with SCDHs were performed for 2 hours at 37 °C. At the end of the incubation 
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period, the media was collected and added to an equal volume of acetonitrile containing 0.06 ng/μL d5-
diazepam. Cocktail incubations with cryopreserved hepatocytes were performed for 30 minutes or 1 hour 
at 37 °C, media was collected at the end of the incubation and added to an equal volume of acetonitrile 
containing d5-diazepam. All incubation samples were centrifuged at 13,000 rpm for 10 minutes. The 
supernatant was removed and stored at 4 °C until analysis.  
The CYP assay metabolites were analyzed using an Agilent 6460 triple quadrupole mass spectrometer 
(Agilent Technologies, Santa Clara, CA) in the University of Washington Mass Spectrometry center as 
described by Liu et al., with minor modifications [14]. Briefly, HPLC separation was achieved using an 
Agilent XDB C18 2.1 x 150 mm, 5 μm column. Compounds were eluted at a flow rate of 0.25 mL/min, using 
the following gradient of 0.1 % formic acid in water (solvent A) and 0.1 % formic acid in acetonitrile (solvent 
B): for the first 1.5 minutes, 99 % solvent A, a linear decrease to 70 % solvent A until 4 minutes, maintained 
at 70 % solvent A until 6 minutes, a linear decrease to 25 % solvent A until 9 minutes and held at 25 % 
solvent A until 13 minutes to wash and cycled back to initial conditions. The column was allowed to re-
equilibrate for 4 minutes before the next sample was injected.  
Results and Discussion  
The University of Wisconsin has made WiCell® lines available to researchers for well over a decade [15]. 
This has made them some of the most widely used hESC lines in research, and in particular the most 
commonly used hESC lines in SCDH research, specifically the H1 and H9 lines [11, 16-35]. To be useful in 
preclinical drug metabolism and toxicity screening, SCDHs must demonstrate consistent and reproducible 
activity of drug metabolism proteins, in particular the oxidative CYP enzymes. In addition, it would be ideal 
if SCDHs demonstrate metabolic activities comparable to human primary hepatocytes. We sought to 
further investigate the state of SCDHs as they compare to cryopreserved human hepatocytes, with 
emphasis on the expression and functional capacity of drug-metabolizing enzymes. In addition, when 
evaluating CYP activity versus primary hepatocytes, it’s important to take pharmacogenetic variability into 
account. To demonstrate the utility of SCDHs in pharmacogenetic predictive screening, we also sought to 
genetically profile the commonly used WiCell® hESC lines, focusing on CYP2D6 in our analysis. 
Hepatocyte differentiation and gene expression 
Hepatocyte differentiation was performed using a published protocol [11, 12]. Briefly, this protocol is 
broken into three stages to induce hepatocyte differentiation: first the priming stage primes the cells to the 
definitive endoderm lineage [11, 33, 36], secondly the differentiation stage induces hepatocyte 
differentiation to form hepatoblast cells, and finally the maturation stage allows for final differentiation and 
maturation of the resulting hepatocytes. This differentiation protocol yielded SCDHs which morphologically 
resemble hepatocytes by displaying the hepatocyte cuboidal morphology and bi-nucleated cells (Figure 1A 
and B). In addition, the SCDHs were immunocytochemically positive for AFP, albumin, HNF4α and CYP3A 
(Figure 1C). Positive immunocytochemical staining was uniform across the wells with the exception of 
colonies of cells that failed to differentiate.  
In order to evaluate the maturity level of SCDHs and gain a better understanding of their potential utility 
in preclinical drug metabolism screens, gene expression profiling of select pluripotency markers, 
hepatocytes markers, transcription factors, drug-metabolizing enzymes and transporters was done. This 
expression profiling was performed for SCDHs at each stage of differentiation, hESCs, cryopreserved 
hepatocytes, HepaRG cells, human fetal liver tissue and human adult liver tissue. HepaRG cells are a cell line 
derived from a human adult hepatocarcinoma patient, which resemble the bi-potential hepatoblast cell 
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[37-39]. These cells can be cultured in their hepatoblast, or undifferentiated state, and then undergo a 
differentiation process to form both biliary epithelial cells and hepatocytes [37-39]. HepaRG cells express 
many of the drug-metabolizing enzymes and more closely resemble primary hepatocytes than the 
commonly used HepG2 cells [39]. To determine if SCDHs retain stem cell characteristics, the pluripotency 
markers NANOG, OCT4 and SOX2 were evaluated. All results are reported as fold change compared to 
differentiated HepaRG cells, with GUSB as the housekeeping gene. From the gene expression profiling, 
NANOG, OCT4, and SOX2 expression dropped as differentiation progressed from stem cell to SCDHs (Figure 
2), suggesting the cells are undergoing a differentiation process and are not retaining their pluripotency. 
Notably, expression of NANOG and OCT4 in SCDHs was similar to expression in differentiated HepaRG cells, 
which was below the level of expression in fetal liver tissue (Figure 2). SOX2 expression in SCDHs was more 
variable between the different cell lines, and ranged from 0.4- to 15-fold compared to differentiated 
HepaRG cells, while SOX2 expression in fetal liver tissue ranged from 0.4- to 7-fold compared to 




Figure 1. SCDH photomicrographs and immunocytochemistry. (A,B) Photomicrographs depicting H1 and H9 
SCDHs, respectively, at each stage of differentiation; hESC, Definitive Endoderm (DE), Hepatoblast, and 
Hepatocyte. (C) Immunocytochemistry results for albumin, α-fetoprotein (AFP), hepatocyte nuclear factor 4α 
(HNF4α), and CYP3A on Day 17 SCDHs. Positive staining is indicated in green, DAPI was used to stain nuclei, 
shown in blue. 
A similar expression pattern was observed for three hepatocyte markers (AFP, ALB and HNF4α), with 
expression increasing from stem cells through differentiation to SCDHs (Figure 2). For albumin, expression 
in SCDHs was lower than the expression in differentiated HepaRG cells, fetal and adult liver tissues. For 
HNF4α, expression in SCDHs was comparable to expression in fetal and adult liver tissues, though lower 
than differentiated HepaRG cells (Figure 2). With regard to AFP, SCDHs expressed AFP to a much greater 
extent than differentiated HepaRG cells, ranging from 2800- to 13000-fold higher than HepaRG cells (Figure 
2). Expression of AFP in fetal liver tissue ranged from 3600- to 30000-fold higher than HepaRG cells, 
indicating that SCDHs expressed AFP at levels comparable to fetal liver tissue. As expected, AFP expression  
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Figure 2. SCDH gene exp. characterization. qRT-PCR results shown as fold change compared to differentiated HepaRG cells, which was 
set to 1. GUS-B was used as a housekeeping gene. For all stem cell and SCDH samples, error bars represent a pool of triplicate 
biological replicates and triplicate technical replicates. For all other samples, error bars represent triplicate technical replicates. 
HepaRG Undiff represents undifferentiated HepaRG cells; HepaRG Diff represents differentiated HepaRG cells; FL1, FL2, FL3, FL4, FL5, 
FL6 represent fetal liver tissue 1, 2, 3, 4, 5, 6, respectively; HL161 and HL167 represent human liver bank samples 161 and 167, 
respectively. 
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was minimally expressed in adult liver tissues. The persistent expression of AFP in SCDHs is in accordance 
with published reports indicating a high retention of AFP expression in SCDHs. Overall, SCDHs appear to 
express the hepatocyte markers AFP, ALB, and HNF4α at levels comparable to fetal liver tissue, indicating a 
close resemblance to a fetal state hepatocyte. 
Transcription factors which regulate drug metabolizing enzymes and transporters were evaluated. The 
transcription factors constitutive androstane receptor (CAR), pregnane X receptor (PXR) and aryl 
hydrocarbon receptor (AhR) were selected because they regulate many of the hepatic phase I and II drug-
metabolizing enzymes and transporters [40, 41]. The expression of CAR, PXR and AhR in SCDHs was minimal 
(Supplemental Figure 1). The expression of AhR in SCDHs was comparable to that in fetal liver tissues, while 
the expression of CAR and PXR in SCDHs was lower than that in fetal liver tissues.  
The expression of CYPs and flavin containing monooxygenases (FMO) were evaluated. With regard to 
FMOs, FMO1 is normally expressed to a greater extent in the fetal liver, and so can be used as another 
marker to evaluate how fetal-like SCDHs are. Indeed, from gene expression profiling FMO1 was highly 
expressed in fetal liver tissue, at levels 20- to 50-fold higher than that in differentiated HepaRG cells, while 
FMO1 expression was undetected in adult liver tissues (Figure 2). FMO1 expression in SCDHs increased 
through differentiation, up to 7- to 13- fold higher than differentiated HepaRG cells (Figure 2). While SCDHs 
retain high expression of FMO1, it was lower than that in fetal liver tissue. The CYP enzymes CYP3A4 and 
CYP3A7 also exhibit differential expression between fetal and adult liver, with CYP3A7 being the 
predominant isoform in fetal liver and CYP3A4 being predominant in the adult liver. This pattern was also 
observed between our fetal and adult liver tissue samples. CYP3A4 was detected in only one SCDH sample, 
with expression well below (0.0003-fold) that observed in HepaRG cells (Figure 2). CYP3A7 was detected in 
two SCDH samples, at 4.5- and 11.8-fold higher than HepaRG cells. Additionally, CYP3A7 expression in 
SCDHs was below expression levels in fetal liver tissue (Figure 2). From these data, SCDHs retain expression 
of CYP3A7, though CYP3A7 expression was lower than fetal liver tissue, indicating an overall lack of CYP3A 
expression in SCDHs. CYP 1A2, 2C19 and 2D6 were undetectable in SCDHs (Supplemental Figure 1). CYP2A6 
was expressed in SCDHs, at levels slightly above adult liver tissue, though below those observed in fetal 
liver tissue (Supplemental Figure 1). CYP2B6 was undetectable in fetal liver tissue samples, but was 
expressed in SCDHs, though at levels below adult liver tissue (Supplemental Figure 1). CYP 2C8, 2C9 and 2E1 
were detectable in SCDHs, but at levels much lower than expression in adult liver tissue, though 
comparable to expression in fetal liver tissue (Supplemental Figure 1). Overall, there was minimal 
expression of the hepatic CYP enzymes in SCDHs, with the exception of the fetal CYP3A7 enzyme. The low 
expression of CYP enzymes in SCDHs would result in low functional activity and was unexpected given that 
HNF4α was expressed at a level consistent with fetal and adult liver tissue. HNF4α is known to have a role 
in supporting the constitutive expression of CYP enzymes in human hepatocytes [42]. Given the relative 
expression of HNF4α, we would expect higher CYP expression in the SCDHs. The expression of P450 
oxidoreductase (POR) was also evaluated. POR is essential for normal function of the CYP enzymes - it is 
needed for electron transfer from NADPH to the CYP [43, 44]. POR expression in SCDHs was below that 
expressed in HepaRG differentiated cells, ranging from 0.07- to 0.56-fold (Figure 2). This expression was 
also well below that found in fetal and adult liver tissues (Figure 2). Interestingly, the undifferentiated hESC 
samples exhibited higher POR expression than SCDHs. A potential reason for the higher expression of POR 
in stem cells could be its use in supporting other CYP enzymes. For example, CYP26 plays an important role 
in embryonic stem cells to promote cell differentiation through retinoid signaling [45, 46]. The low 
expression of POR in SCDHs may contribute to the observed low functional activity for the drug-
metabolizing CYP enzymes.  
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To examine expression of phase II drug-metabolizing enzymes, UDP-glucuronosyltransferases (UGT) and 
glutathione-S-transferases (GST) were evaluated. Expression of UGT2B7 in SCDHs was comparable to fetal 
liver tissue (Figure 2). Expression of UGT1A1 in SCDHs was comparable to expression in both fetal and adult 
liver tissue and UGT1A6 expression was comparable to that in adult liver tissue (Supplemental Figure 1). In 
contrast, expression of UGT2B4 in SCDHs was below that of both fetal and adult liver tissue (Supplemental 
Figure 1). In general, for GSTT1, GSTM1 and GSTP1 there was largely no difference in expression between 
stem cells and SCDHs (Supplemental Figure 1). For the H1 and H9 cell lines evaluated in the gene expression 
profiling, no polymorphisms for the GSTs were detected in the DMET genotyping analysis.  
To examine the expression of drug transporters in SCDHs, P-gp, BCRP, MRP2, OATP1B1, OATP1B3, and 
ATP7B mRNA levels were measured. ATP7B is a copper transporting ATPase expressed in the liver, and is 
responsible for transporting copper from hepatocytes into the bile [47]. Mutations in ATP7B are associated 
with Wilson’s disease, a disorder in copper metabolism with manifestations in the liver and the brain [47]. 
Expression of ATP7B was up-regulated in SCDHs, compared to stem cells. The expression in SCDHs was 
slightly higher than differentiated HepaRG cells, fetal and adult liver tissue (Supplemental Figure 1). P-gp 
was expressed in SCDHs at levels comparable to that in fetal liver tissue and below HepaRG differentiated 
cells and adult liver tissue (Figure 2). BCRP expression was higher in SCDHs compared to HepaRG cells, fetal 
and adult liver tissue (Figure 2). Expression of OATP1B1 and OATP1B3 was minimal in SCDHs, and well 
below that in fetal and adult liver tissue (Supplemental Figure 1). Lastly, while MRP2 mRNA was detected in 
SCDHs, it was below the expression levels in HepaRG cells, fetal and adult liver tissue (Supplemental Figure 
1). Similar to the other results obtained for gene expression, some transporters were minimally expressed 
(OATP1B1, OATP1B3, MRP2), while some were similar to that in fetal liver tissue (P-gp and ATP7B), with the 
exception of BCRP which was highly expressed in SCDHs.  
 
Figure 3. CYP3A induction. qRT-PCR results for SCDHs incubated with the inducer rifampicin or phenobarbital, 
shown as fold change compared to SCDHs incubated with DMSO, which was set to 1. GUS-B was used as a 
housekeeping gene. SCDH Rif represents SCDHs incubated with rifampicin; SCDH Pheno represents SCDHs 
incubated with phenobarbital.  
 
SCDHs were incubated with the canonical inducers rifampicin and phenobarbital and effects on CYP3A4, 
CYP3A7, CAR and PXR expression were evaluated. Results are reported as fold change compared to SCDHs 
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incubated with a DMSO vehicle control (Figure 3). In this instance, basal expression of CYPs 3A4 and 3A7 
was detected in SCDHs. CYP3A4 expression was induced by rifampicin and phenobarbital. Phenobarbital 
induced CYP3A4 in SCDHs to levels comparable with a fetal liver tissue sample. CYP3A7 and CAR expression 
was induced by phenobarbital. Phenobarbital induced CYP3A7 in SCDHs to levels comparable with an adult 
liver tissue sample. The gene expression results reported here indicate SCDHs are capable of responding to 
the inducers rifampicin and phenobarbital.  
Overall, gene expression profiling of SCDHs indicates they are largely immature hepatocytes, especially 
with regard to the CYP enzymes. With regards to AFP, CYP3A7 and FMO1 expression, SCDHs appear to 
more closely resemble fetal hepatocytes. This suggests that even though SCDHs are not currently in a fully 
differentiated, or mature, state they may be useful in studying drug-metabolism in neonates, or potentially 
as a test system to investigate the ontogeny of drug-metabolizing enzymes. However, further investigation 
of drug-metabolizing enzyme expression throughout the differentiation process and comparison to a more 
extensive sampling of fetal tissues at different ages than what was utilized in this study would be 
warranted. If SCDHs are to be used in conjunction with, or as an alternative to, cryopreserved hepatocytes 
a differentiation protocol that generates more mature hepatocytes is needed. One potential method that 
may enhance SCDH differentiation includes the use of small molecules in place of less chemically defined 
proteins. Another method that may enhance SCDH differentiation is the manipulation of microRNAs 
(miRNAs) during the cell culture process that contribute to hepatocyte development. miRNAs regulate 
many genes, making them similar to transcription factors, and therefore potential regulators of cellular 
processes such as differentiation. For example, knockdown of miRNAs that may contribute to maintenance 
of a pluripotent, or stem cell state, may allow further maturation of SCDHs. Alternatively, over-expression 
of miRNAs known to normally be expressed in mature hepatocytes may also allow for further maturation of 
SCDHs. Lastly, there is the potential of 3D culture systems to enhance SCDH differentiation and functional 
maturation. Culturing the SCDHs in a 3D, or microphysiological, culture system that more closely represents 
the true in vivo micro-environment of a hepatocyte is another potential method to enhance SCDH 
differentiation. 
 CYP cocktail assay 
To assess the metabolic function of the CYP enzymes in SCDHs, a CYP cocktail assay was utilized and 
metabolite formation was measured using LC-MS/MS. For SCDHs, all metabolites were below the lower 
limit of quantitation (LLOQ) with the exception of 6-OH-testosterone, indicating some measurable activity 
of CYP3A (Table 1). 6-OH-testosterone was detectable for both H1 and H9 SCDHs, with activity at 1.27 
pmol/min/106 cells. In contrast, activity in primary hepatocytes was 92.9 pmol/min/106 cells. The LLOQ for 
6-OH-testosterone was 0.312 μM. Positive control primary and cryopreserved hepatocytes generated 
measurable metabolites for all compounds tested, indicating the incubation assay and LC-MS/MS method 
was working. Based on the CYP cocktail assay, SCDHs do not display detectable CYP activity, except for 
CYP3A, which was expected based on gene expression profiling. Overall, these results demonstrate an 
absence of functional drug-metabolizing enzyme activity in SCDHs, corroborating what has largely been 
reported for SCDHs to date; that they are immature compared to cryopreserved hepatocytes, especially 
with regards to drug-metabolizing enzyme functions.  
Genotyping 
We focused on CYP2D6 in our analysis in utilizing SCDHs for genotype-phenotype predictions, given its 
highly polymorphic nature and role in metabolizing about 20 % of marketed drugs [9, 10]. CYP2D6 is the 
most polymorphic drug-metabolizing enzyme, with more than 63 functional gene alleles 
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(www.cypalleles.ki.se/cyp2d6.htm), including polymorphisms that result in gene deletion, defective splicing 
and gene duplication. Having an in vitro cell system, such as genotyped SCDHs, would allow for more 
thorough characterization of pharmacogenetic effects on drug metabolism, and potentially their impact on 
the pharmacokinetics of a new chemical entity early on in drug development.  In particular, for compounds 
found to be highly metabolized by CYP2D6, where polymorphisms may lead to therapeutic failure or a drug 
toxicity risk, this may aid in making go/no-go decisions or help to inform possible inclusion of 
genotyping/phenotyping of patients in clinical studies. Select genotyping results for CYP2D6 can be found in 
Table 2. Analysis of CYP2D6 copy number found H1 to have 1 copy, with all other lines having 2 copies of 
CYP2D6. No CYP2D6 duplications were found, indicating there is no representative of a CYP2D6 ultra-rapid 
metabolizer within these cell lines (Table 2).  
Table 1. CYP cocktail assay results. Results are reported as mean (SD). SCDH activity, n = 6; primary hepatocyte 
activity, n = 2. LLOQ = lower limit of quantitation 









CYP3A 0.312 1.27 (0.361) 92.9 (1.45) 
CYP1A 0.125 BLQ 14.9 (0.365) 
CYP2A6 0.0084 BLQ 0.0431 (0.0168) 
CYP2B6 0.0039 BLQ 1.62 (0.169) 
CYP2C8 0.017 BLQ 0.917 (0.066) 
CYP2C9 0.013 BLQ 2.85 (0.00544) 
CYP2D6 0.0017 BLQ 2.27 (0.122) 
CYP2E1 1 BLQ 12.1 (0.695) 
Table 2. CYP2D6 genotyping results. A summary of the CYP2D6 copy number and genotyping results for 
WiCell® hESC lines H1, H7, H9, H13, and H14. Based on genotyping results a prediction for expected CYP2D6 





H1 H7 H9 H13 H14 
Copy Number 
 
 1 2 2 2 2 
CYP2D6*2 
2850C>T 
AM_12261 T C/T C/T T/T C/T 
CYP2D6*3 
2549delA 
AM_12267 A A/A A/A A/A A/A 
CYP2D6*4 
1846G>A 
AM_12274 G G/A G/G G/G G/A 
CYP2D6*6 
1707delT 
AM_12276 T T/T T/T T/T T/T 
CYP2D6*9 
2613_2615delAGA 
AM_12264 AGA AGA/AGA AGA/AGA AGA/AGA AGA/AGA 
CYP2D6*10 
100C>T 
AM_12285 C C/T C/T C/C C/T 
CYP2D6*17 
1023C>T 
AM_12280 C C/C C/C C/C C/C 
CYP2D6*29 
3183G>A 
AM_12255 G G/G G/G G/G G/G 
CYP2D6*35 
4180G>C 
AM_12247 C C/C C/C C/C C/C 
CYP2D6*41 
2988G>A  
AM_12257 A G/G G/A G/G G/G 
Predicted 
Phenotype 
 PM-IM IM IM-EM EM IM 
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Lines H7 and H14 were both found to have one copy of the CYP2D6*4 null allele, with no other 
polymorphisms associated with aberrant function detected. With regard to the CYP2D6*41 allele, line H9 
was found to be heterozygous for this allele, and the single gene copy of CYP2D6 in line H1 also contains 
the CYP2D6*41 allele. Taking the copy number and genotyping data together, we have made predictions 
regarding CYP2D6 phenotype in these cell lines, as found in Table 2. To summarize, we predict line H1 to be 
a CYP2D6 poor-intermediate metabolizer, lines H7 and H14 to be intermediate metabolizers, line H9 to be 
an intermediate-extensive metabolizer, depending on activity from the CYP2D6*41 allele, and line H13 to 
be an extensive metabolizer. Select genotyping results for other CYP enzymes can be found in Table 3. 
Notably, all 5 hESC lines were found to be homozygous for CYP3A5*3, a null allele, meaning they are all 
CYP3A5 non-expressers. In addition, the H14 line is homozygous for CYP2C9*2 and H1 is heterozygous for 
CYP2C9*3; both of these alleles result in decreased CYP2C9 activity and have documented effects on in 
vitro and in vivo pharmacokinetics and clinical drug response, e.g. warfarin [48]. Genotyping results for 
Phase II/III enzymes can be found in Table 4. Lines H7, H13, and H14 are heterozygous for the UGT1A1*28 
allele, which results in reduced activity of UGT1A1 [49]. Clinically, reduced activity of the UGT1A1*28 allele 
is associated with development of toxicity following administration of the chemotherapeutic irinotecan 
(The Pharmacogenomics Knowledge Base: https://www.pharmgkb.org) [50]. Additionally, lines H1, H7, and 
H14 are heterozygous for the NAT2*5 allele and H13 is homozygous for this allele, likely resulting in slow 
acetylator status for these cell lines. The Affymetrix DMET™ array genotyping results in their entirety can be 
accessed from Gene Expression Omnibus (GEO): (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc 
=GSE53889; accession: GSE53889). 
Table 3. CYP genotyping results. A summary of CYP genotyping results for WiCell® hESC lines H1, H7, H9, H13, 
and H14. 
Common Name Probe Set 
ID 
H1 H7 H9 H13 H14 
CYP1A2*1F 
-163C>A 
















AM_11426 C/C C/T C/C C/T C/T 
CYP2B6*6 
15631G>T 
AM_11411 G/G No Call No Call G/G G/T 
CYP2C9*2 
3608C>T 
AM_10100 C/C C/C C/C C/C T/T 
CYP2C9*3 
42614A>C 
AM_10113 A/C A/A A/A A/A A/A 
CYP2C19*2 
19154G>A 
AM_10070 G/G G/G G/G G/G G/G 
CYP2C19*3 
17948G>A 
AM_10068 G/G G/G G/G G/G G/G 
CYP2C19*17 
-806C>T 
AM_10053 C/T C/C C/T C/C C/C 
CYP2E1*2 
1132G>A 
AM_10249 G/G G/G G/G G/G G/G 
CYP3A5*3 
6986A>G 
AM_14759 G/G G/G G/G G/G G/G 
CYP3A5*6 
14690G>A 
AM_14748 G/G G/G G/G G/G G/G 
CYP3A7*1C 
-232A>C 
AM_14791 A/A A/A A/A A/A A/A 
CYP3A7*1C 
-284T>A 
AM_14796 T/T T/T T/T T/T T/T 
CYP3A7*2 
26041C>G 
AM_14781 C/C C/C C/C C/C C/C 
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For use in preclinical drug metabolism screening assays, vendors commonly offer pooled donor lots of 
hepatocytes to mitigate the effects of interindividual variability. With this in mind, the H1 line has one copy 
of CYP2D6, making it a predicted poor metabolizer in human hepatocytes, meaning SCDHs generated from 
hESC line H1 may not metabolize CYP2D6 probe drugs at a level comparable to primary hepatocytes. In this 
case it would be important to ensure that a lot of single donor human primary hepatocytes used for 
comparison with H1-derived SCDHs have been characterized as a CYP2D6 poor metabolizer. Regarding 
other CYP isozymes, a commonly used activity test in SCDHs is an ethoxyresorufin-O-deethylase (EROD) 
assay for CYP1A activity and inducibility [11, 19, 51, 52]. Our genotyping results show the H1 line to be 
homozygous and H9 to be heterozygous for CYP1A2*1F, an allele which has been shown to influence the 
magnitude of inducibility of CYP1A2 [48, 53]. 
Table 4. Phase II/III genotyping results. A summary of genotyping results for phase II and III enzymes for 
WiCell® hESC lines H1, H7, H9, H13, and H14. 
Common Name Probe Set 
ID 
H1 H7 H9 H13 H14 
ALDH2 
1510G>A 


























AM_14978 A/G G/G G/G G/G G/G 
NAT2*5 
341T>C 
AM_15001 C/T C/T T/T C/C C/T 
SULT1A1*2 
638G>A 
AM_11005 A/G A/G A/G G/G A/G 
TPMT*2 
238G>C 
AM_13986 G/G G/G G/G G/G G/G 
TPMT*3B 
460G>A 
AM_13980 G/G G/G G/G G/G G/G 
TPMT*3C 
719A>G 
AM_13973 A/A A/A A/A A/A A/A 
TPMT*4 
626-1G>A 
















AM_13465 T/T T/T T/T C/T T/T 
ABCB1 
1236C>T 
AM_14612 C/T C/T C/T C/T C/T 
ABCB1 
2677G>T>A 
AM_14592 G/T G/T G/T G/T G/T 
ABCB1 
3435C>T 
AM_14581 C/T C/T C/T C/T C/T 
ABCG2 
421C>A 
AM_13688 C/C C/C C/C C/C C/C 
SLCO1A2 
404A>T 
AM_10533 A/A A/A A/A A/A A/A 
SLCO1A2 
516A>C 
AM_10531 A/A A/A A/A A/A A/A 
SLCO1B1*1B 
388A>G 
AM_10496 A/G A/A A/G A/A A/A 
SLCO1B1*4 
463C>A 
AM_10498 C/C C/C A/C C/C C/C 
SLCO1B3 
334G>T 
AM_10481 G/G G/G G/G G/G G/G 
SLCO1B3 
699A>G 
AM_10482 A/A A/A A/A A/A A/A 
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The genotyping data presented here is important to better understand the activity of metabolizing 
enzymes and transporters when evaluating metabolism of probe substrates in SCDHs, particularly when 
being used as a marker to evaluate the efficiency of differentiation of SCDHs. The Affymetrix DMET™ array 
used for genotyping in this study provides a thorough evaluation of the major known polymorphisms in 
ADME-related genes. However, there are examples when calls were not made (e.g. CYP2B6*6), such that if 
evaluating activity of these proteins, individual genotyping for these alleles may be necessary. This study 
only reports results for the five commonly used WiCell® lines, however this approach to genotyping should 
be considered for all hESC and human iPSC lines used as a target cell source for models of drug metabolism 
and toxicity. In particular, if a bank of hESC or iPSCs is to be established then the use of a genotyping array, 
such as the Affymetrix DMET™ array, should be implemented with results readily available to researchers. 
As the cost of whole genome sequencing continues to decrease, it will become an attractive alternative to 
targeted arrays such as what we employed, with the caveat that mining these large data sets for specific 
ADME-related polymorphisms is currently challenging.  
CYP2D6*41 reverse-transcription PCR Assay 
Aberrant splicing resulting from the CYP2D6*41 polymorphism was assessed ex vivo with human liver 
tissue and in vitro using SCDHs. To assess differentiation in the SCDHs used for CYP2D6*41 analysis, gene 
expression of AFP, ALB, HNF4α, CYP2D6, CYP3A4, NANOG and OCT4 was evaluated, results are reported as 
fold change compared to cryopreserved hepatocyte log HUM4012 (Figure 4A). While expression of HNF4α 
in SCDHs is comparable to that seen in cryopreserved hepatocytes, expression levels of albumin and 
CYP3A4 were lower than that of cryopreserved hepatocytes. Conversely, expression of AFP in SCDHs is 
higher than that expressed in cryopreserved hepatocytes, corroborating our previous gene expression 
results. Expression of NANOG and OCT4 in SCDHs was lower than expression in the undifferentiated hESC 
lines and comparable to cryopreserved hepatocytes. In the case of CYP2D6, expression levels were 
detectable in H9 SCDHs, though below expression in cryopreserved hepatocytes, while H1 SCDHs were 
below the limit of quantitation. This differential expression is in line with the genotyping results for these 
two cell lines.  
Earlier identification and characterization of the 2988G>A SNP, now referred to as CYP2D6*41 (Human 
CYP Allele nomenclature website: http://www.imm.ki.se/), revealed it to cause a splicing defect, resulting in 
exon 6 being skipped, and a predictor of CYP2D6 intermediate metabolizer phenotype [54-56]. Toscano et 
al. identified the splice variant lacking exon 6 in liver samples genotyped for CYP2D6*41 (2988G>A) and 
found that 2988G>A causes favorable formation of a splice product that lacks exon 6, with up to 7-fold 
increased levels of the splice variant [55]. We wanted to further elucidate the penetrance of CYP2D6*41 
aberrant splicing and, in addition, we wanted to demonstrate the potential utility of SCDHs to evaluate 
genotype-phenotype relationships for CYP2D6. Results from PCR amplification using primers Exon5/8For3 
and Exon5/8Rev3 are shown in Figure 4B and C. The expected amplicons for samples homozygous for 
CYP2D6*41 are 438-bp, for heterozygous samples both 438-bp and 579-bp, and for non-carriers of 
CYP2D6*41 579-bp. As shown in Figure 4C, certain samples (lanes 1 and 2) homozygous for *41 have a 579-
bp amplicon as well as the expected 438-bp alternatively spliced band, indicating the unexpected presence 
of exon 6, and demonstrating incomplete penetrance of this splicing defect. In addition, one sample (lane 
7) heterozygous for *41 only displays the 579-bp amplicon, indicating presence of exon 6 in all mRNA 
produced (or suppression of expression of the *41 allele). It should be noted that the aberrantly spliced 
band may be present, but simply was below the limit of detection in our RT-PCR assay. The H1 SCDH 
sample, with one copy of CYP2D6 containing *41 displays the expected exon 6 spliced band at 438-bp, as 
seen in Figure 4C, lane 13. No properly spliced band was detected, as expected. Our SCDH CYP2D6*41 
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heterozygous cell, line H9 (lane 14) also displays a band indicating aberrant exon 6 splicing, but only a weak 
band for the properly spliced transcript fragment. Again, bands may be present, but simply were below the 
limit of detection in our RT-PCR assay; based on observations from the qRT-PCR that CYP2D6 expression in 
H1 SCDHs is below the limit of quantitation and in H9 SCDHs is 16 fold lower than that of cryopreserved 
hepatocytes based on ∆∆CT calculations. We are able to show similar results for CYP2D6*41 splicing in our 
SCDHs as seen in the liver tissue samples. Overall, our results corroborate the findings of Toscano et al. and 
provide further evidence that CYP2D6*41 displays incomplete penetrance.  
 
 
Figure 4. CYP2D6*41 reverse transcription PCR assay. (A) Gene expression results shown as fold change 
compared to cryopreserved hepatocyte lot HUM4012, which was set to 1. (B) Schematic representation of 
the CYP2D6 gene. The polymorphism of interest is 2988G>A located between exons 6 and 7, and results in 
exon 6 skipping. To detect the presence of exon 6 in CYP2D6, a 579-bp PCR fragment spanning a region from 
exon 5 to exon 8 was amplified with primers Exon5/8For3 (F Primer) and Exon5/8Rev3 (R Primer). If exon 6 is 
skipped due to the presence of CYP2D6*41, a smaller PCR fragment of 438-bp is expected. (C) Agarose 
electrophoretic analysis of reverse transcription PCR products of the CYP2D6 region indicated in (B) from 
human liver tissue samples and Day 17 SCDHs generated from WiCell® lines H1 and H9. Lane M, 100bp 
marker; lane 1 *41/*41; lane 2 *41/*41; lane 3 *1A/*1A; lane 4 *1A/*1A; lane 5 *2A/*2A; lane 6 *1A/*1A; 
lane 7 *1A/*41; lane 8 *4A/*41; lane 9 *1A/*41; lane 10 *2A/*41; lane 11 *2A/*41; lane 12 *9A/*41; lane 13 
H1 *41; lane 14 H9 *41 carrier. 
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Conclusions 
Pluripotent stem cells have a high self-renewal capability and can differentiate into any cell type in the 
body, making them an attractive tool for researchers in drug discovery and development. SCDHs offer a 
promising new tool for use in hepatic drug metabolism and toxicity screens, adding to available human 
derived cell models. There has been extensive research on SCDHs for this purpose, and while there is 
evidence SCDHs express drug-metabolizing enzymes, they remain in a de-differentiated state. This indicates 
there is a significant need for improvement on generating and characterizing SCDHs, particularly with 
regards to their metabolic capacity as it compares to primary hepatocytes. In this study, gene expression 
profiling and functional assays of CYP activity indicate SCDHs are largely immature hepatocytes, lacking 
significant CYP expression and activity. Based on gene expression profiling, SCDHs most closely resemble 
fetal hepatocytes, especially with regards to AFP, CYP3A7 and FMO1 expression. Functional assay of 
enzyme activity in SCDHs using a CYP cocktail revealed only minor CYP3A activity, below that observed in 
primary hepatocytes. These data demonstrates that more work needs to be done to promote the maturity 
of SCDHs. Enhanced expression and function of drug-metabolizing enzymes in SCDHs would make them a 
more viable option to supplant primary hepatocytes in the pharmaceutical industry for drug 
metabolism/liver toxicity assays. In addition, SCDHs may provide an improved in vitro system for evaluating 
genotype-phenotype relationships of the CYP enzymes and their impact on drug metabolism and toxicity. 
This is the first published report of genotyping in the WiCell® hESC lines with regards to ADME-relevant 
polymorphisms. In addition, we are able to demonstrate the CYPP2D6*41 splicing defect displays 
incomplete penetrance, with similar results observed in SCDHs and liver tissue. The pharmacogenetic data 
provided here is vital to understanding metabolism profiles when these hESC lines are used as a target 
tissue source for models of drug metabolism and toxicity. 
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Supplemental Figure 1. SCDH gene expression characterization. Additional qRT-PCR results shown as fold 
change compared to differentiated HepaRG cells, which was set to 1. GUS-B was used as a housekeeping 
gene. For all stem cell and SCDH samples, error bars represent a pool of triplicate biological replicates and 
triplicate technical replicates. For all other samples, error bars represent triplicate technical replicates. 
HepaRG Undiff represents undifferentiated HepaRG cells; HepaRG Diff represents differentiated HepaRG 
cells; FL1, FL2, FL3, FL4, FL5, FL6 represent fetal liver tissue 1, 2, 3, 4, 5, 6, respectively; HL161 and HL167 
represent human liver bank samples 161 and 167, respectively. 
 
